Antibody specifically binding to CD38, and preparation method therefor and use thereof
CAR-T cells were prepared by nano-antibody that specifically binds to CD38, which solved the problem of AML recurrence and achieved efficient AML cell killing and tumor-inhibiting effects.
Patent Information
- Application Number
- PCT/CN2024/090396
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-04-28
- Publication Date
- 2024-11-21
AI Technical Summary
Although existing AML treatments can relieve the disease, almost all patients will eventually relapse, lacking effective immunotherapeutic agents to completely remove acute myeloid leukemia cells.
A nanoantibody that specifically binds CD38 was developed to prepare CAR-T cells to achieve more effective killing by specifically identifying and targeting CD38-expressing AML cells.
CAR-T cells showed high specific in vitro cytotoxicity and in vivo tumor inhibition effects, which could effectively inhibit CD38-positive tumor growth and reduce self-killing, improving cell expansion and lasting anti-tumor drug efficacy.
Smart Images

Figure PCTCN2024090396-FTAPPB-I100001 
Figure PCTCN2024090396-FTAPPB-I100002 
Figure PCTCN2024090396-FTAPPB-I100003
Abstract
Description
Antibodies specifically binding to CD38 and their preparation and use Technical Field
[0001] The present invention relates to the field of engineered immunotherapy, and in particular to an antibody specifically binding to CD38, and a preparation method and application thereof. Background Art
[0002] Acute myeloid leukemia (AML) is a cancer of the bone marrow blood cells, characterized by the rapid growth of immature blood cells ("blasts") that accumulate in the bone marrow and blood and interfere with normal blood cells. AML can spread to other organs, such as the liver, spleen, and brain. If not treated, AML progresses rapidly and is usually fatal within weeks or months. AML has several subtypes, and the treatment and results for the subtypes can be different. Typically, AML is initially treated with chemotherapy, sometimes together with targeted therapy drugs. Subsequently, the patient may continue to receive stem cell transplantation, other chemotherapy, surgery, or radiotherapy. AML is most common in the elderly, some of whom are not healthy enough to receive intensive chemotherapy and therefore have poor clinical outcomes. Although current therapies for AML typically result in disease remission, almost all patients eventually relapse. Effective immunotherapeutics are needed to treat AML.
[0003] Chimeric antigen receptors (CARs) are artificial receptors that mimic the functions of T cell receptors, combining the recognition and binding specificity of antigens and antibodies, or ligands and receptors, with the ability of effector T cells to kill recognized tumor cells. CARs are composed of a signal peptide, an antigen recognition region (ligand or single-chain antibody or Fab fragment), a transmembrane region, and a series of T cell signal transduction domains (CD28, CD3, and CD137 intracellular signaling domains) connected in sequence. After T cell modification, the surface-expressed CAR first binds to tumor cell surface antigens through the antigen recognition region. Then, through its signal transduction domain, it transmits the activation signal intracellularly, thereby specifically activating the T cell's anti-tumor cell killing activity. The DNA sequence expressing the CAR is cloned into a lentiviral expression vector and used to infect T cells isolated from the patient's blood, causing them to express the corresponding CAR on their surface. These modified T cells are then infused back into the patient's body. The modified T cells can then target and kill tumor cells expressing the relevant antigen within the patient's body, effectively eliminating the tumor cells.
[0004] The advantages of camel-derived antibodies (or single-domain antibodies) include their stability, good water solubility, low immunogenicity, higher affinity, smaller molecular weight, and improved tissue penetration compared to traditional antibodies. Single-domain antibodies can be used as diagnostic tools and for the delivery of CAR-T and targeted drugs.
[0005] Therefore, there is an urgent need in this field to develop a new CAR immune cell with stronger specificity and / or lower immunogenicity and optimal affinity for the treatment of acute myeloid leukemia.
[0006] Summary of the Invention
[0007] The purpose of the present invention is to provide an antibody with high affinity and high biological activity and capable of specifically recognizing CD38 antigen and its application.
[0008] In a first aspect of the present invention, there is provided a Nanobody that specifically binds to CD38, wherein the complementarity determining region (CDR) region of the VHH chain in the Nanobody has the following CDR1, CDR2 and CDR3:
[0009] (a) CDR1: the sequence of which is shown in SEQ ID No: 6 or 11;
[0010] (b) CDR2: the sequence of which is shown in SEQ ID No: 7, 9, 12 or 14;
[0011] (c) CDR3: Its sequence is shown in SEQ ID No: 8, 10, 13 or 15.
[0012] In another preferred embodiment, the complementarity determining region (CDR) region of the VHH chain in the Nanobody is selected from the following group:
[0013] (Y1) CDR1 of SEQ ID NO: 6, CDR2 of SEQ ID NO: 14, and CDR3 of SEQ ID NO: 15;
[0014] (Y2) CDR1 set forth in SEQ ID NO: 6, CDR2 set forth in SEQ ID NO: 9, and CDR3 set forth in SEQ ID NO: 10;
[0015] (Y3) CDR1 set forth in SEQ ID NO: 6, CDR2 set forth in SEQ ID NO: 7, and CDR3 set forth in SEQ ID NO: 8;
[0016] (Y4) CDR1 set forth in SEQ ID NO: 6, CDR2 set forth in SEQ ID NO: 9, and CDR3 set forth in SEQ ID NO: 10;
[0017] (Y5) CDR1 shown in SEQ ID NO: 11, CDR2 shown in SEQ ID NO: 12, and CDR3 shown in SEQ ID NO: 13.
[0018] In another preferred embodiment, the CDR1, CDR2 and CDR3 are separated by the framework regions FR1, FR2, FR3 and FR4 of the VHH chain.
[0019] In another preferred embodiment, the nanobody that specifically binds to CD38 includes humanized antibodies, camel-derived antibodies, and chimeric antibodies.
[0020] In another preferred embodiment, the amino acid sequence of the Nanobody that specifically binds to CD38 is as shown in any one of SEQ ID NOs: 1 to 5.
[0021] In another preferred example, the amino acid sequence of the VHH chain of the Nanobody is selected from the following group: SEQ ID NO: 1 to 5, or a combination thereof.
[0022] In another preferred example, the CDR region of the Nanobody VHH chain comprises an amino acid sequence having a sequence similarity of at least 80%, preferably at least 90%, more preferably at least 95%, even more preferably at least 99% to any one of SEQ ID NOs: 1 to 5.
[0023] In another preferred example, the amino acid sequence of the Nanobody VHH chain CDR region comprises one or more amino acid substitutions compared to any one of SEQ ID NOs: 1 to 5, preferably conservative amino acid substitutions.
[0024] In another preferred embodiment, any one of the above amino acid sequences further includes a derivative sequence that is optionally added, deleted, modified and / or substituted with at least one (such as 1-3, preferably 1-2, more preferably 1) amino acid and can retain the ability to specifically bind to CD38.
[0025] In another preferred embodiment, the CD38 is CD38 of a human or non-human mammal.
[0026] In another preferred embodiment, the CD38 is CD38 from humans, mice, rats, or non-human primates (such as monkeys).
[0027] In the second aspect of the present invention, a multivalent antibody or an antibody against multiple epitopes that specifically binds to CD38 is provided, wherein the multivalent antibody or the antibody against multiple epitopes comprises at least one antibody element against a CD38 epitope, and the antibody element is the anti-CD38 nanobody described in the first aspect of the present invention.
[0028] In another preferred embodiment, the anti-CD38 multivalent antibody or the antibody targeting multiple epitopes comprises one or more anti-CD38 nanobodies.
[0029] In another preferred embodiment, the anti-CD38 antibody includes a monomer, a bivalent body (bivalent antibody), a tetravalent body (tetravalent antibody), and / or a multivalent body (multivalent antibody).
[0030] In another preferred embodiment, the anti-CD38 antibody comprises one or more VHH chains having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 5.
[0031] In another preferred embodiment, the anti-CD38 antibody comprises two VHH chains having the amino acid sequences shown in SEQ ID NOs: 1 to 5.
[0032] In another preferred embodiment, the antibody is selected from: animal-derived antibodies, chimeric antibodies, humanized antibodies, or a combination thereof.
[0033] In a third aspect of the present invention, a recombinant protein is provided, wherein the recombinant protein has:
[0034] (i) the Nanobody that specifically binds to CD38 as described in the first aspect of the invention, or the multivalent antibody or antibody against multiple epitopes that specifically binds to CD38 as described in the second aspect of the invention; and
[0035] (ii) optionally a tag sequence to facilitate expression and / or purification.
[0036] In another preferred embodiment, the antibody is a multivalent antibody.
[0037] In another preferred embodiment, the tag sequence includes an Fc tag, an HA tag, a Flag tag and a 6His tag.
[0038] In another preferred embodiment, the Fc tag comprises mIgG2aFc.
[0039] In another preferred embodiment, the recombinant protein specifically binds to CD38 protein.
[0040] In a fourth aspect of the present invention, a chimeric antigen receptor (CAR) fusion protein is provided, characterized in that the chimeric antigen receptor (CAR) fusion protein comprises from the N-terminus to the C-terminus:
[0041] (i) an antigen-binding domain that specifically binds to CD38, said antigen-binding domain comprising the Nanobody according to the first aspect of the invention;
[0042] (ii) transmembrane domain;
[0043] (iii) at least one costimulatory domain; and
[0044] (iv) Activation domain.
[0045] In another preferred embodiment, the antigen binding domain is monovalent or multivalent.
[0046] In another preferred embodiment, the antigen binding domain is derived from the Nanobody described in the first aspect of the present invention or the recombinant protein described in the third aspect of the present invention.
[0047] In another preferred embodiment, the CAR has the structure shown in Formula Ia:
[0048] L-VHH-FH-TM-C-CD3ζ (Ia)
[0049] Where,
[0050] Each "-" is independently a connecting peptide or a peptide bond;
[0051] L is the signal peptide sequence;
[0052] VHH is the antigen-binding domain that specifically binds to CD38;
[0053] F stands for Flag tag;
[0054] H is the hinge region;
[0055] TM is the transmembrane domain;
[0056] C is the costimulatory signaling domain;
[0057] CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ (including wild type, or mutants / modified forms thereof).
[0058] In another preferred embodiment, the L is a signal peptide derived from CD8.
[0059] In another preferred embodiment, the L comprises the amino acid sequence shown in SEQ ID NO: 20.
[0060] In another preferred embodiment, the amino acid sequence of the VHH is shown in any one of SEQ ID NOs: 1 to 5.
[0061] In another preferred embodiment, the H comprises the hinge region of CD28.
[0062] In another preferred embodiment, the TM includes a transmembrane region derived from CD28.
[0063] In another preferred embodiment, the amino acid sequences of H and TM comprise the sequence shown in SEQ ID No: 22.
[0064] In another preferred embodiment, the C is a transmembrane region of a protein selected from the group consisting of CD28, 4-1BB, CD8a or a combination thereof.
[0065] In another preferred embodiment, the C comprises a co-stimulatory signal molecule derived from 4-1BB.
[0066] In another preferred embodiment, the C comprises the amino acid sequence shown in SEQ ID No: 23.
[0067] In another preferred embodiment, the CD3ζ comprises the amino acid sequence shown in SEQ ID No: 24
[0068] In another preferred embodiment, the CAR fusion protein has an amino acid sequence shown in any one of SEQ ID NOs: 25-29.
[0069] In a fifth aspect of the present invention, an antibody-drug conjugate is provided, wherein the antibody-drug conjugate comprises:
[0070] (a) the Nanobody of the first aspect of the invention, the multivalent antibody or antibody against multiple epitopes of the second aspect of the invention, or the recombinant protein of the third aspect of the invention; and
[0071] (b) a conjugated moiety conjugated to the antibody portion, wherein the conjugated moiety is selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, or a combination thereof.
[0072] In another preferred embodiment, the antibody portion and the coupling portion are coupled via a chemical bond or a linker.
[0073] In the sixth aspect of the present invention, a polynucleotide is provided, which encodes a protein selected from the following group: the nanobody described in the first aspect of the invention, or the multivalent antibody or antibody against multiple epitopes described in the second aspect of the invention, the recombinant protein described in the third aspect of the invention, or the CAR fusion protein described in the fourth aspect of the invention.
[0074] In the seventh aspect of the present invention, an expression vector is provided, wherein the expression vector contains the polynucleotide described in the sixth aspect of the present invention.
[0075] In another preferred embodiment, the expression vector is selected from the following group: DNA, RNA, viral vector, plasmid, transposon, other gene transfer systems, or a combination thereof.
[0076] In another preferred embodiment, the expression vector is a lentiviral vector.
[0077] In the eighth aspect of the present invention, a host cell is provided, which contains the expression vector described in the seventh aspect of the present invention, or the polynucleotide described in the sixth aspect of the present invention is integrated into its genome, or expresses the nanoantibody described in the first aspect of the present invention, the multivalent antibody or antibody against multiple epitopes described in the second aspect of the present invention, the recombinant protein described in the third aspect of the present invention, or the CAR fusion protein described in the fourth aspect of the present invention.
[0078] In another preferred embodiment, the cell is an isolated cell, and / or the cell is a genetically engineered cell.
[0079] In another preferred embodiment, the cells are mammalian cells.
[0080] In another preferred embodiment, the cells are T cells.
[0081] In another preferred embodiment, the host cell is an engineered immune cell.
[0082] In another preferred embodiment, the engineered immune cells are selected from the following group:
[0083] (i) Chimeric antigen receptor αβ T cells (CAR-T cells);
[0084] (ii) chimeric antigen receptor γδ T cells (CAR-T cells);
[0085] (iii) chimeric antigen receptor NKT cells (CAR-NKT cells);
[0086] (iv) chimeric antigen receptor NK cells (CAR-NK cells);
[0087] (v) Chimeric antigen receptor macrophages.
[0088] In the ninth aspect of the present invention, a method for preparing engineered immune cells is provided, comprising the following steps: transducing the nucleic acid molecule described in the sixth aspect of the present invention or the vector described in the seventh aspect of the present invention into T cells or NK cells, thereby obtaining the engineered immune cells, wherein the engineered immune cells express the CAR fusion protein described in the fourth aspect of the present invention.
[0089] In another preferred embodiment, the method further comprises the step of performing functional and effectiveness testing on the obtained engineered immune cells.
[0090] In the tenth aspect of the present invention, a preparation is provided, which contains the nanobody described in the first aspect of the invention, the multivalent antibody or the antibody against multiple epitopes described in the second aspect of the invention, the recombinant protein described in the third aspect of the invention, the CAR fusion protein described in the fourth aspect of the invention, or the vector described in the seventh aspect of the invention, or the host cell described in the eighth aspect of the invention, and a pharmaceutically acceptable carrier, diluent or excipient.
[0091] In another preferred embodiment, the host cell is an engineered immune cell.
[0092] In the eleventh aspect of the present invention, a pharmaceutical composition is provided, comprising:
[0093] (i) the Nanobody of the first aspect of the invention, or the multivalent antibody or antibody against multiple epitopes of the second aspect of the invention, or the recombinant protein of the third aspect of the invention, or an immune cell expressing the CAR fusion protein of the fourth aspect of the invention; and
[0094] (ii) a pharmaceutically acceptable carrier.
[0095] In another preferred embodiment, the conjugated portion of the immunoconjugate is a drug, a toxin, and / or a therapeutic isotope.
[0096] In another preferred embodiment, the pharmaceutical composition further contains other drugs for treating immune system diseases or tumor diseases.
[0097] In another preferred embodiment, the pharmaceutical composition is used to prepare a drug for preventing and / or treating diseases or conditions associated with CD38.
[0098] In another preferred embodiment, the disease or condition associated with CD38 is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), or a combination thereof.
[0099] In the twelfth aspect of the present invention, a kit is provided, which contains the nucleic acid molecule described in the sixth aspect of the present invention, the recombinant protein described in the third aspect of the present invention, or the vector described in the seventh aspect of the present invention.
[0100] In another preferred embodiment, the kit is used to prepare immune cells expressing the receptor CAR fusion protein described in the fourth aspect of the present invention.
[0101] In the thirteenth aspect of the present invention, there is provided the use of the nanoantibody described in the first aspect of the present invention, or the multivalent antibody or antibody against multiple epitopes described in the second aspect of the present invention, or the recombinant protein described in the third aspect of the present invention, or the immune cell expressing the CAR fusion protein described in the fourth aspect of the present invention for the preparation of a medicament for preventing and / or treating CD38-related tumors.
[0102] In the fourteenth aspect of the present invention, a method for treating a disease is provided, comprising administering to a subject in need of treatment: the nanoantibody described in the first aspect of the invention, or the multivalent antibody or antibody against multiple epitopes described in the second aspect of the invention, or the recombinant protein described in the third aspect of the invention, or immune cells expressing the CAR fusion protein described in the fourth aspect of the invention.
[0103] In another preferred embodiment, the disease is a tumor that is positive for CD38 expression.
[0104] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one.
[0105] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0106] FIG1 shows target cell surface antigen expression.
[0107] Figure 2 shows the CAR positivity rate of CD38-CAR T cells.
[0108] FIG3 shows the expression of CD38 on the surface of WT CD38-CAR T cells.
[0109] FIG4 shows the changes in the CAR positivity rate of CD38-CAR T cells during the expansion culture process.
[0110] FIG5 shows the viability and expansion fold of CD38-CAR T cells during the expansion culture process.
[0111] FIG6 shows the analysis of the binding ability of CD38 CAR to CD38 antigen.
[0112] FIG7 shows the killing results of CD38-CAT T cells on Hela-WT and CD38-overexpressing Hela cells (RTCA method).
[0113] FIG8 shows the results of CD38-CAR T killing of CD38-positive target cells (luciferase method).
[0114] FIG9 shows the inhibitory effect of CD38-CAR T on Molm13 cells inoculated into immunodeficient mice and the changes in mouse body weight after reinfusion.
[0115] FIG10 shows the CAR positive rate after CAR-NK92 sorting.
[0116] FIG11 shows the results of CAR-NK92 killing of tumor cells (luciferase method).
[0117] FIG12 shows the results of multiple rounds of killing by CAR-N92K. DETAILED DESCRIPTION
[0118] After extensive and in-depth research, the inventors unexpectedly obtained a class of anti-CD38 antibodies with excellent affinity and high anti-tumor activity for the first time. Specifically, after a large number of screenings, the inventors obtained for the first time multiple nanobodies that specifically bind to CD38. Based on the nanobodies, the present invention further prepared recombinant antibodies and humanized antibodies, as well as chimeric antigen receptors targeting CD38. Based on alpaca heavy chain antibodies that specifically bind to CD38, the present invention provides CAR-T cells that have better affinity, stronger specificity for target antigens, and lower immunogenicity than traditional antibodies. The CAR-T cells of the present invention have excellent target cell killing activity and in vivo tumor inhibition effects. The present invention was completed on this basis.
[0119] Specifically, the present invention utilizes human CD38 antigen protein to immunize alpacas to obtain a high-quality immune nanobody gene library. CD38 protein molecules are then coupled to an ELISA plate to display the correct spatial structure of the CD38 protein. This antigen is then used to screen the immune nanobody gene library (alpaca heavy chain antibody phage display gene library) using phage display technology to obtain nanobody genes specific for the CD38 protein. These genes are then transferred to Escherichia coli to obtain a nanobody strain that can be efficiently expressed in E. coli and has high specificity.
[0120] the term
[0121] In order to more easily understand the present disclosure, some terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms should have the meaning given below. Other definitions are set forth throughout the application.
[0122] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0123] As used herein, the terms "comprising" or "including" may be open, semi-closed, or closed. In other words, the terms also include "consisting essentially of" or "consisting of."
[0124] Sequence identity is determined by comparing two aligned sequences along a predetermined comparison window (which can be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein) and determining the number of positions at which identical residues occur. Typically, this is expressed as a percentage. The measurement of sequence identity of nucleotide sequences is a method well known to those skilled in the art.
[0125] As used herein, the terms "heavy chain variable region" and "V H ” can be used interchangeably.
[0126] As used herein, the terms "variable region" and "complementarity determining region (CDR)" are used interchangeably.
[0127] In the present invention, the terms "antibody of the present invention," "single-domain antibody of the present invention," "protein of the present invention," or "polypeptide of the present invention" are used interchangeably to refer to antibodies that specifically bind to CD38, such as proteins or polypeptides having a heavy chain variable region (such as the amino acid sequences shown in SEQ ID NOs: 1-5). These may or may not contain an initial methionine.
[0128] CD38
[0129] Human CD38 (also known as cyclic ADP ribose hydrolase) is a 45kDa, single-chain, type II transmembrane glycoprotein. Its overall structure consists of an N-terminal intracellular domain, a single transmembrane span, and a C-terminal extracellular domain. This extracellular domain catalyzes the synthesis and degradation of cyclic adenosine diphosphate ribose (cADPR). CD38 is a marker of cell activation and has been associated with HIV infection, leukemia, myeloma, and solid tumors.
[0130] CD38 can be detected on the surface of many immune cells, including B cells and NK cells. CD38 is also highly expressed on the surface of various tumors, including multiple myeloma, diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), plasma cell leukemia (PCL), acute myeloid leukemia (AML), follicular lymphoma (FL), mantle cell lymphoma (MCL), and lung cancer.
[0131] Antibody
[0132] As used herein, the term "antibody" refers to immunoglobulins, which are tetrapeptide chains composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds.
[0133] As used herein, the terms "single-domain antibody (VHH)" and "nanobody" have the same meaning and refer to the cloning of the variable region of an antibody heavy chain to construct a single-domain antibody (VHH) consisting of only a single heavy chain variable region. This is the smallest antigen-binding fragment with complete function. Typically, an antibody naturally lacking the light chain and heavy chain constant region 1 (CH1) is first obtained, and then the variable region of the antibody heavy chain is cloned to construct a single-domain antibody (VHH) consisting of only a single heavy chain variable region.
[0134] Existing antibody numbering schemes include:
[0135] 1. The Kabat scheme (Kabat et al., 1991) is based on the location of regions of high sequence variation between sequences of the same domain type, with antibody heavy (VH) and light (Vλ and Vκ) variable domains numbered differently.
[0136] 2. The Chothia program (Al-Lazikani, 1997) is identical to Kabat's, but corrects the position of the insertion annotation around the first VH complementarity-determining region (CDR) to correspond to the structural loop. Similarly, the enhanced Chothia program (Abhinandan and Martin, 2008) further structurally corrects the insertion position.
[0137] 3. In contrast to these Kabat-like schemes, IMGT (Lefranc, 2003) and AHo (Honegger and Plückthun, 2001) both define unique schemes for variable domains of antibodies and T-cell receptors (TCRs) (Vα and Vβ). Therefore, equivalent residue positions can be easily compared between domain types. IMGT and AHo differ in the number of positions they annotate (128 and 149, respectively) and the locations where they consider indels to occur.
[0138] The amino acid composition and arrangement order of the constant region of immunoglobulins (Ig) heavy chains vary, resulting in different antigenic properties. Consequently, immunoglobulins can be divided into five classes, or isotypes, namely IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being μ, δ, γ, α, and ε, respectively. Igs within the same class are further divided into subclasses based on the amino acid composition of their hinge regions and the number and location of disulfide bonds in the heavy chains. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. Light chains are classified as either kappa or lambda chains, depending on the constant region. Each of the five Ig classes can have either kappa or lambda chains. The subunit structures and three-dimensional configurations of different immunoglobulin classes are well known in the art.
[0139] The antibody light chain of the present invention may further comprise a light chain constant region, wherein the light chain constant region comprises a human or murine κ, λ chain or a variant thereof.
[0140] In the present invention, the antibody heavy chain described in the present invention may further comprise a heavy chain constant region, wherein the heavy chain constant region comprises human or murine IgG1, IgG2, IgG3, IgG4 or variants thereof. The sequence of approximately 110 amino acids near the N-terminus of the antibody heavy and light chains varies greatly and is the variable region (Fv region); the remaining amino acid sequence near the C-terminus is relatively stable and is the constant region. The variable region includes three hypervariable regions (HVRs) and four framework regions (FRs) with relatively conserved sequences. The three hypervariable regions determine the specificity of the antibody and are also called complementarity determining regions (CDRs). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) consists of three CDR regions and four FR regions, arranged in the order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The three CDR regions of the light chain are referred to as LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain are referred to as HCDR1, HCDR2, and HCDR3.
[0141] The term "murine antibody," as used herein, refers to anti-CD38 monoclonal antibodies prepared according to the knowledge and skill in the art. These antibodies are prepared by injecting a subject with the CD38 antigen, followed by isolation of hybridomas expressing antibodies with the desired sequence or functional properties. In a preferred embodiment of the present invention, the murine CD38 antibody or antigen-binding fragment thereof may further comprise a light chain constant region of a murine kappa or lambda chain, or variants thereof, or a heavy chain constant region of a murine IgG1, IgG2, IgG3, or variants thereof.
[0142] The term "chimeric antibody" refers to an antibody formed by fusing the variable region of a mouse antibody with the constant region of a human antibody, which can reduce the immune response induced by the mouse antibody.
[0143] The term "humanized antibody", also known as CDR-grafted antibody, refers to an antibody produced by transplanting mouse CDR sequences into the human antibody variable region framework, that is, different types of human germline antibody framework sequences. Humanized antibodies can overcome the heterologous reactions induced by chimeric antibodies due to the large amount of mouse protein components. Such framework sequences can be obtained from public DNA databases or published references including germline antibody gene sequences. In order to avoid a decrease in immunogenicity and the resulting decrease in activity, the human antibody variable region framework sequence can be subjected to minimal reverse mutation or back mutation to maintain activity.
[0144] The term "antigen-binding fragment of an antibody" (or simply "antibody fragment") refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., CD38). It has been shown that fragments of a full-length antibody can be used to perform the antigen-binding function of an antibody. Examples of binding fragments encompassed by the term "antigen-binding fragment of an antibody" include
[0145] (i) Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains;
[0146] (ii) F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region;
[0147] (iii) an Fd fragment consisting of the VH and CH1 domains;
[0148] (iv) An Fv fragment consisting of the VH and VL domains of a single arm of an antibody.
[0149] Fv antibodies contain the variable regions of the antibody heavy chain and light chain, but no constant region, and are the smallest antibody fragments with all antigen-binding sites. Generally, Fv antibodies also include a polypeptide linker between the VH and VL domains and are able to form the structure required for antigen binding.
[0150] The term "CDR" refers to one of the six hypervariable regions within the variable domain of an antibody that primarily contributes to antigen binding. One of the most commonly used definitions of the six CDRs is provided by Kabat EA et al. (1991) Sequences of proteins of immunological interest. NIH Publication, No. 91-3242).
[0151] The term "epitope" or "antigenic determinant" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds (e.g., a specific site on the CD38 molecule). An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or non-consecutive amino acids in a unique spatial conformation.
[0152] The terms "specific binding", "selective binding", "selectively binds" and "specifically binds" refer to the binding of an antibody to a predetermined epitope on an antigen. -7 M, for example, less than approximately 10 -8 M, 10 -9 M or 10 10 Binds with an affinity (KD) of M or less.
[0153] The term "competitive binding" refers to an antibody that recognizes the same epitope (also referred to as an antigenic determinant) or a portion of the same epitope on the extracellular region of CD38 as the monoclonal antibody of the present invention and binds to the antigen. An antibody that binds to the same epitope as the monoclonal antibody of the present invention refers to an antibody that recognizes and binds to the amino acid sequence of CD38 recognized by the monoclonal antibody of the present invention.
[0154] The term "KD" or "Kd" refers to the dissociation equilibrium constant for a particular antibody-antigen interaction. Typically, the antibodies of the invention exhibit dissociation equilibrium constants of less than about 10 -7 M, for example, less than about 10 -8 M, 10 -9 M or 10 -10 It binds to CD38 with a dissociation equilibrium constant (KD) of M or less.
[0155] As used herein, the term "antigenic determinant" refers to a discrete three-dimensional site on an antigen that is recognized by the antibodies or antigen-binding fragments of the present invention.
[0156] The present invention includes not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Therefore, the present invention also includes fragments, derivatives and analogs of the antibodies.
[0157] In the present invention, antibodies include murine, chimeric, humanized, or fully human antibodies prepared using techniques well known to those skilled in the art. Recombinant antibodies, such as chimeric and humanized monoclonal antibodies, including human and non-human portions, can be prepared using recombinant DNA techniques well known in the art.
[0158] As used herein, the term "monoclonal antibody" refers to an antibody secreted by a clone derived from a single cell. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. The cell may be a eukaryotic, prokaryotic, or phage clone.
[0159] In the present invention, the antibodies can be monospecific, bispecific, trispecific, or more multispecific.
[0160] In the present invention, the antibodies of the present invention also include conservative variants thereof, which refer to polypeptides in which no more than 10, preferably no more than 8, more preferably no more than 5, and most preferably no more than 3 amino acids are replaced with amino acids having similar or similar properties, compared to the amino acid sequence of the antibodies of the present invention. These conservative variant polypeptides are preferably generated by making amino acid substitutions according to Table A below.
[0161] Table A
[0162] Anti-CD38 humanized antibody
[0163] The present invention provides a humanized anti-CD38 antibody (hereinafter referred to as CLDN 18.2 antibody). Specifically, the present invention provides a highly specific and high-affinity humanized antibody against CD38, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region (VH) amino acid sequence and the light chain comprises a light chain variable region (VL) amino acid sequence.
[0164] There are two common options for human framework regions in antibody humanization: known mature antibodies or human germline sequences. The framework regions of known mature antibodies often contain somatic mutation sites, which may confer potential immunogenicity. Compared to mature antibodies, human germline sequence framework regions are theoretically less immunogenic and more structurally flexible, with increased plasticity and the ability to accommodate diverse CDR regions. Human antibody germline genes have a certain frequency of usage in the human body. Humanized antibodies using frequently used germline framework regions exhibit advantages such as low immunogenicity, high expression levels, and structural stability.
[0165] In a preferred embodiment of the present invention, multiple factors (including similarity and human usage frequency) were considered during humanization. After extensive experimental screening, optimal framework sequences were selected for humanization. The humanized antibody germline framework region was selected for CDR grafting. This resulted in a more stable humanized antibody structure, higher expression levels, lower immunogenicity, and improved drugability.
[0166] In another preferred embodiment, the heavy chain constant region and / or light chain constant region may be a humanized heavy chain constant region or light chain constant region. More preferably, the humanized heavy chain constant region or light chain constant region is a heavy chain constant region of human IgG1, IgG2, etc., or a human kappa or lambda light chain constant region.
[0167] In another preferred embodiment, the sequence formed by adding, deleting, modifying and / or replacing at least one amino acid sequence is preferably an amino acid sequence with a homology of at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95%.
[0168] The antibody of the present invention may be a double-chain or single-chain antibody, and may preferably be a fully humanized antibody.
[0169] The antibody derivatives of the present invention can be single-chain antibodies and / or antibody fragments, such as Fab, Fab', (Fab')2, or other antibody derivatives known in the art, as well as any one or more of IgA, IgD, IgE, IgG, IgM antibodies or other subtypes of antibodies.
[0170] The antibody of the present invention may be a humanized antibody, a CDR-grafted and / or modified antibody targeting CD38.
[0171] In the above content of the present invention, the number of added, deleted, modified and / or substituted amino acids is preferably not more than 40% of the total number of amino acids in the initial amino acid sequence, more preferably not more than 35%, more preferably 1-33%, more preferably 5-30%, more preferably 10-25%, more preferably 15-20%.
[0172] Antibody preparation
[0173] Any method suitable for producing monoclonal antibodies can be used to produce the CD38 antibodies of the present invention. For example, animals can be immunized with linked or naturally occurring CD38 proteins or fragments thereof. Suitable immunization methods can be used, including adjuvants, immunostimulants, repeated booster immunizations, and one or more routes of administration.
[0174] Any suitable form of CD38 can be used as an immunogen (antigen) to generate non-human antibodies specific for CD38 and screen the biological activity of the antibodies. The immunogen can be used alone or in combination with one or more immunogenicity enhancers known in the art. The immunogen can be purified from a natural source or produced in genetically modified cells. The DNA encoding the immunogen can be genomic or non-genomic (e.g., cDNA) in origin. The DNA encoding the immunogen can be expressed using a suitable genetic vector, including but not limited to adenoviral vectors, baculoviral vectors, plasmids, and non-viral vectors.
[0175] Humanized antibodies can be selected from any class of immunoglobulins, including IgM, IgD, IgG, IgA, and IgE. Similarly, any class of light chain can be used in the compounds and methods herein. Specifically, kappa, lambda chains, or variants thereof can be used in the compounds and methods of the present invention.
[0176] The sequence of the DNA molecule of the antibody of the present invention or its fragment can be obtained by conventional techniques, such as PCR amplification or genomic library screening. In addition, the coding sequences of the light chain and heavy chain can be fused together to form a single-chain antibody.
[0177] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the propagated host cells by conventional methods.
[0178] In addition, artificial synthesis methods can also be used to synthesize relevant sequences, especially when the fragment length is relatively short. Generally, by first synthesizing multiple small fragments and then connecting them, very long fragments of sequence can be obtained. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art.
[0179] The term "nucleic acid molecule" refers to DNA molecules and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded, but are preferably double-stranded DNA. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
[0180] The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. In one embodiment, the vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated.
[0181] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins.
[0182] The term "host cell" refers to a cell into which an expression vector has been introduced. The host cell can be a prokaryotic cell, such as a bacterial cell, a lower eukaryotic cell, such as a yeast cell, or a higher eukaryotic cell, such as a plant or animal cell (e.g., a mammalian cell).
[0183] The steps of transforming host cells with recombinant DNA described in the present invention can be carried out using techniques well known in the art. The transformants obtained can be cultured using conventional methods, and the transformants express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, conventional culture medium is used under appropriate conditions.
[0184] Typically, the transformed host cells are cultured under conditions suitable for expression of the antibodies of the present invention. The antibodies of the present invention are then purified using conventional immunoglobulin purification procedures, such as protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, ion exchange chromatography, hydrophobic chromatography, molecular sieve chromatography, or affinity chromatography, among other conventional separation and purification methods well known to those skilled in the art.
[0185] The resulting monoclonal antibodies can be characterized by conventional means. For example, the binding specificity of the monoclonal antibodies can be determined by immunoprecipitation or in vitro binding assays such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).
[0186] Antibody preparations
[0187] Antibodies exhibit varying stability in different formulation buffers, manifesting as changes in charge heterogeneity, degradation of antibody molecules, and aggregation. These changes in quality properties are related to the physical and chemical properties of the antibodies themselves. Therefore, during the antibody drug development process, it is necessary to screen formulation buffers suitable for each antibody based on its physical and chemical properties. Currently, commonly used antibody formulation buffer systems include phosphate buffer, citrate buffer, and histidine buffer. Depending on the properties of the antibody, varying concentrations of salt ions or excipients such as sorbitol, trehalose, and sucrose, as well as appropriate amounts of surfactants such as Tween, are added to maintain antibody stability.
[0188] Pharmaceutical composition
[0189] The present invention also provides a composition. In a preferred embodiment, the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment or its fusion protein or its ADC or corresponding CAR-T cell, and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH value may vary with the properties of the formulated substance and the condition to be treated. The prepared pharmaceutical composition can be administered by conventional routes, including (but not limited to): intratumoral, intraperitoneal, intravenous, or local administration.
[0190] The antibodies of the present invention can also be expressed in cells by nucleotide sequences for cell therapy, for example, the antibodies are used in chimeric antigen receptor T cell immunotherapy (CAR-T) and the like.
[0191] The pharmaceutical composition of the present invention can be used to directly bind to CD38 protein molecules, and thus can be used to prevent and treat CD38-related diseases. In addition, other therapeutic agents can also be used simultaneously.
[0192] The pharmaceutical composition of the present invention contains a safe and effective amount (e.g., 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the above-mentioned monoclonal antibody of the present invention (or its conjugate) and a pharmaceutically acceptable carrier or excipient. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, using physiological saline or an aqueous solution containing glucose and other adjuvants by conventional methods. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 1 μg / kg body weight to about 5 mg / kg body weight per day. In addition, the polypeptide of the present invention can also be used in conjunction with other therapeutic agents.
[0193] When using a pharmaceutical composition, a safe and effective amount of the pharmaceutical composition is administered to a mammal, wherein the safe and effective amount is generally at least about 10 μg / kg body weight, and in most cases does not exceed about 50 mg / kg body weight. Preferably, the dosage is about 10 μg / kg body weight to about 20 mg / kg body weight. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health condition, which are all within the skill of a skilled physician.
[0194] Detection Uses and Kits
[0195] The antibodies of the present invention can be used in detection applications, for example, for detecting a sample to provide diagnostic information.
[0196] In the present invention, the samples used include cells, tissue samples and biopsy specimens. The term "biopsy" as used in the present invention should include all types of biopsies known to those skilled in the art. Therefore, the biopsy used in the present invention can include, for example, tissue samples prepared by endoscopic methods or puncture or needle biopsy of an organ.
[0197] Samples used in the present invention include fixed or preserved cell or tissue samples.
[0198] The present invention also provides a kit containing the antibody (or fragment thereof) of the present invention. In a preferred embodiment of the present invention, the kit further comprises a container, instructions for use, a buffer, etc. In a preferred embodiment, the antibody of the present invention can be fixed to a detection plate.
[0199] The main advantages of the present invention include:
[0200] (a) The single-domain antibody (VHH domain) against CD38 of the present invention has high specificity and optimal affinity.
[0201] (b) The CD38 CAR T cells of the present invention exhibit highly specific in vitro cytotoxicity against CD38-positive target cells.
[0202] (c) The CD38 CAR T cells of the present invention can effectively inhibit the growth of CD38-positive tumors in vivo and show long-lasting anti-tumor efficacy.
[0203] (d) Knockout / weakening of endogenously expressed CD38 in CD38 CAR T cells of the present invention can effectively reduce cell fratricide and enhance the in vivo and in vitro expansion of CAR-T.
[0204] (e) The antibody of the present invention can be used to specifically detect CD38 protein.
[0205] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.
[0206] Example 1. Alpaca antibody screening
[0207] The antibodies were screened from the phage antibody library. The process of establishing the alpaca antibody library is briefly described as follows: the antigen CD38 was mixed with the adjuvant and emulsified, and the alpaca was immunized subcutaneously five times. After the five immunizations, blood samples were collected to separate PBMCs, and the total RNA of the PBMCs was extracted and then reverse transcribed into cDNA. VHH was amplified by nested PCR, and the VHH fragment was inserted into the phagemid. The phage was amplified and harvested to obtain the antibody library.
[0208] CD38 antibody screening was performed by protein panning. The process was briefly described as follows: CD38 antigen was coated overnight, and the antibody library was added after blocking and incubated for 1 hour the next day. After the incubation, the cells were washed 8-10 times, and the bound phages were eluted and amplified. The amplified phages were isolated and purified for the next round of screening.
[0209] After screening for enrichment, the enriched phages are used to infect the host bacteria. Resistance plates are then plated and 96 single clones / pool are randomly selected for culture. The overnight culture supernatant is collected and positive clones are identified by Phage ELISA. Based on the OD values of the phage ELISA-positive antigen wells (Pro) and the difference (Pro / PVA) from the control wells (PVA), multiple single clones are selected for sequencing. Sequences with sequencing anomalies are further eliminated, and clones with identical sequences are merged.
[0210] result
[0211] Five single-domain antibodies that bind to CD38 were finally obtained based on the affinity ranking of positive monoclonal antibodies and the frequency of occurrence of enriched antibodies. The amino acid sequences and CDR corresponding SEQ ID Nos. are shown in Tables 1, 2, and 3 below.
[0212] Table 1 Amino acid sequences of CD38 single domain antibodies
[0213] Table 2 CDR amino acid sequences of CD38 single domain antibodies
[0214] Table 3 Sequence numbering (SEQ ID No) of CD38 single domain antibodies
[0215] Example 2. Cell culture and construction
[0216] Molm13-Luc cells, KG1-LucG cells, HL60-LucG cells, U937-LucG cells, and K562-LucG cells were cultured in RPMI 1640 medium; 293T and wild-type Hela cells expressing CD38, expressing CLL1, and expressing both CLL1 and CD38 (Hela-WT, Hela-CD38, Hela-CLL1, Hela-CLL1-CD38) were cultured in DMEM medium. All of the above culture media were supplemented with 10% (v / v) fetal bovine serum and 100 U / ml penicillin and streptomycin, 2 mM L-glutamine, and 1 mM sodium pyruvate. Cells were cultured at 37°C, 5% CO2, and saturated humidity.
[0217] Hela cells expressing CD38 are stable cell lines derived from the transfer of the CD38 antigen via a lentiviral vector and are capable of specifically expressing the CD38 protein molecule. Hela cells expressing CLL1 are stable cell lines derived from the transfer of the CLL1 antigen via a lentiviral vector and are capable of specifically expressing the CLL1 protein molecule. Hela cells expressing both CLL1 and CD38 are stable cell lines derived from the transfer of the CLL1-CD38 (T2A-linked) antigen via a lentiviral vector and are capable of specifically expressing both CLL1 and CD38 protein molecules. Molm13-Luc cells are stable cell lines derived from the transfer of a lentivirus expressing firefly luciferase. KG1-LucG cells, HL60-LucG cells, U937-LucG cells, and K562-LucG cells are stable cell lines derived from the transfer of a lentivirus expressing firefly luciferase-GFP (T2A-linked).
[0218] The expression of target cell surface antigens is shown in Figure 1. Hela-CD38 is a cell overexpressing CD38, Hela-CLL1 is a cell overexpressing CLL1, Hela-CLL1-CD38 is a cell overexpressing CLL1 and CD38, Hela-WT and K562 are double-negative cells for CLL1 and CD38, Molm13 is a single-positive cell for CD38, and HL60, KG1, and U937 are double-positive cells for CLL1 and CD38.
[0219] Example 3. CD38 CAR vector construction and virus preparation
[0220] The CD38 CAR gene consists of a CD8 signal peptide, a VHH or scFv that recognizes CD38, the CD8 hinge and transmembrane region, the 4-1BB signal region, and the CD3z signal region. The CD38 CAR gene is placed under the EF1α (EF-1α) promoter to create a CD38 CAR expression vector. These vectors are numbered B1, B2, B3, B5, and B8 based on their VHH sequences. The CD38 CAR expression vector constructed using the scFv of the CD38-targeting antibody daratumumab is named dara.
[0221] The amino acid sequence of the CD38 C-CAR of this embodiment is shown in SEQ ID No: 25-29, and the amino acid sequence of the CAR based on the scFv of daratumumab is shown in SEQ ID No: 30.
[0222] 2.5×10 6 293T cells were seeded in 150 cm 2The cells were cultured in 10% FBS-containing DMEM medium in a culture dish at 37°C, 5% CO2 and saturated humidity overnight before transfection.
[0223] The next day, the auxiliary plasmid and CD38 CAR expression vector were added to a centrifuge tube containing 13.8 mL of Opti MEM medium, and 80 μg of PEI was added to the tube to obtain a mixture. The mixture was allowed to stand at room temperature for 20 minutes, and then 12 mL of Opti MEM medium was supplemented to obtain the transfection medium. For transfection, after removing the medium, the 293T cells were incubated with the transfection medium for 4-6 hours, and then the transfection medium was replaced with 20 mL of DMEM medium containing 2% FBS. After 72 hours, the culture medium was collected and centrifuged at 3000 g and 4 ° C for 15 minutes. The supernatant was further centrifuged at 27000 g and 4 ° C for 2 hours. The precipitate was collected and resuspended with 400 μL of pre-chilled X-VIVO medium to obtain a CD38 CAR lentiviral suspension and kept at 4 ° C overnight. The next day, the viral suspension was aliquoted for further use.
[0224] Example 4. Preparation of CD38-CAR T cells
[0225] T cells were cultured in X-VIVO medium supplemented with 1% human albumin, 4% serum replacement, and 300 IU / mL human interleukin-2 (hIL-2). Pan T cells were activated by incubation with CD3 / CD28 Dynabeads at a 1:1 ratio (CD3 / CD28 Dynabeads:T cells) and 300 IU / mL IL-2. After 2 days, the activated cells were divided into two aliquots. One aliquot was directly transfected with a virus to produce wild-type CD38-CAR T cells (WT CD38-CAR T cells), while the other aliquot was first electroporated to knock out the CD38 gene and then transfected with a virus to produce CD38KO CD38-CAR T cells.
[0226] The preparation process of WT CD38-CAR T was as follows: After 2 days of activation of CD3 / CD28 Dynabeads, the Dynabeads were removed using a magnetic column and directly incubated at 37°C with 1×10 6 T cells were transfected with the CD38 CAR virus at a cell density of 10 cells / mL. The transfected cells were cultured and expanded. During the culture and expansion process and before cryopreservation, the CAR positivity of the T cells was detected using CD38 antigen, and cell surface CD38 expression was detected using a CD38 antibody. Half of the culture medium was replaced every 2-3 days. WT CD38-CAR T cells were harvested on the 8th day after removing the CD3 / CD28 Dynabeads.
[0227] Preparation of CD38KO CD38-CAR T requires electroporation of CD38 gene in T cells activated with CD3 / CD28 Dynabeads for 2 days. The specific operation is as follows: 0.25 nmol of gRNA targeting CD38 gene and 16.5 μg of Cas9 protein are mixed evenly and incubated at 37°C for 15 minutes to prepare RNP; during the incubation period, 18 μL of supplement buffer is added to 82 μL of Nucleofector Solution to prepare 100 μL of Ionza P3 electroporation buffer; at the same time, CD3 / CD28 Dynabeads are removed using a magnetic column, and 1×10 7 After centrifugation at 400 g for 5 min, the cell pellet was collected. After incubation, 1×10 7 The T cell pellet was added to the RNP and mixed evenly. The cells were then transferred to an electroporation cup and placed in a Lonza 2B electroporator. The electroporation was performed using the FI-115 program. The electroporated cells were incubated with 300 IU / mL IL-2 overnight.
[0228] On the second day after electroporation, 1 × 10 6 T cells were transfected with the CD38 CAR virus at a cell density of 10 cells / mL. The transfected cells were cultured and expanded. During the culture and expansion process and before freezing, the CAR positivity of the T cells was detected using CD38 antigen, and the expression of CD38 on the cell surface was detected using a CD38 antibody. Half of the culture medium was replaced every 2-3 days. CD38KO CD38-CAR T cells were harvested on the 8th day after removing the CD3 / CD28 Dynabeads.
[0229] Figure 2 shows that the expression of CD38 CAR can be detected using CD38 antigen on the surface of T cells after virus transfection.
[0230] Because CD38 protein is present on the surface of T cells, expression of the CD38 CAR can lead to fratricide, resulting in the elimination of CD38-expressing T cells. Figure 3A shows the changes in the percentage of CD38+ cells during cell expansion and culture. In WT CD38-CAR T cells, the percentage of CD38+ cells in B3 and dara cells rapidly decreased to CD38-negative and did not recover during culture. The percentage of CD38+ cells in B1, B2, B5, and B8 cells gradually decreased in the early stages of culture and recovered in the later stages of culture. Figure 3B shows the expression of CD38 on the surface of WT CD38-CAR T cells in each group on the day of cryopreservation. B3 and dara cells were CD38-negative. B1, B2, B5, and B8 cells were partially CD38-positive, similar to NT cells, but the mean fluorescence intensity of the CD38+ fraction of B1, B2, B5, and B8 cells was lower than that of NT cells.
[0231] Similarly, the cannibalism caused by CD38 CAR expression can cause changes in the proportion of CAR+ cells. The dynamic changes in cell surface CD38 CAR expression are shown in Figure 4. In WT CD38-CAR T cells that have not undergone gene editing, the CAR positivity rate continues to increase, while in CD38KO CD38-CAR T cells, the CAR positivity rate does not change dramatically.
[0232] The presence of fratricide also affects cell viability and expansion. Figure 5A shows the changes in cell viability during cell expansion, showing that the viability of CD38KO CD38-CAR T cells is significantly higher than that of WT CD38-CAR T cells. Figure 5B shows the cell expansion fold, showing that the expansion fold of CD38KO CD38-CAR T cells is significantly higher than that of WT CD38-CAR T cells. Figure 5C shows the expansion of WT (KO) CD38-CAR T cells relative to WT (KO) NT cells, showing that the expansion of WT CD38-CAR T cells is significantly weaker than that of WT NT cells.
[0233] Example 5. Analysis of CD38 CAR Antigen Binding Ability
[0234] The CD38 antigen is diluted in a gradient manner and used to calibrate the CAR positivity rate of different CD38-CAR T cells, so as to analyze the binding ability of different CD38 CARs to the CD38 antigen.
[0235] The analysis results are shown in Figure 6. Compared with dara, B1, B2, B3, B5 and B8 can bind to less CD38 antigen, and under the same antigen dosage conditions, they also have higher average fluorescence intensity than dara.
[0236] Example 6. CD38-CAR T cell killing in vitro
[0237] The CD38-CAR T cells obtained above were subjected to an in vitro killing experiment. The RTCA method was used to test the killing ability of CAR-T cells against Hela cell lines whose target cells overexpressed CD38.
[0238] The results are shown in Figure 7 (RTCA assay). Under both effector-target ratios, the NT control group showed no killing of Hela-CD38 cells, while CD38-CAR T cells showed killing of Hela-CD38 cells. WT-dara exhibited some nonspecific killing of Hela-WT cells, but the other groups showed no nonspecific killing of Hela-WT cells.
[0239] Luciferase-labeled tumor target cells are used to test their killing ability. By transferring the luciferase gene into target cells and cloning and screening, stable transfected cell lines KG1-LucG and K562-LucG were obtained. During the experiment, luciferin substrate is added, and the luciferase reacts with luciferin to produce fluorescence. The intensity of the fluorescence can be used to determine the activity of the luciferase, and the cell survival rate can be measured to determine the killing effect of each CAR-T cell.
[0240] Figure 8 shows that at all E:T ratios, NT cells had no killing function, CD38-CAR T cells had a dose-dependent killing effect on KG1-LucG cells, and CD38-CAR T cells had no killing ability on K562-LucG cells.
[0241] In summary, after co-culture of CD38-CAR T cells with target cells (CD38-overexpressing Hela cells, CD38-positive tumor cells, KG1 cells), the target cells can be lysed by CAR T cells targeting CD38; and except for WT-dara, the CD38-CAR T cells in other groups do not have nonspecific killing effects on non-target cells (wild-type Hela cells, and CD38-negative K562 cells).
[0242] Example 7. In vivo efficacy study of CD38-CAR T cells
[0243] 4-6 week old NOG-dKO mice were selected and injected with 2×10 6 Molm13-Luc cells. Six days later, tumor burden was assessed by small animal live imaging. Groups were then divided and injected with KO CD38-CAR T cells and NT cells on the same day. Following T cell treatment, tumor burden in mice was assessed by small animal live imaging twice a week.
[0244] The results are shown in Figure 9. Compared to the NT control group, tumor growth was suppressed in mice injected with KO CD38-CAR T cells. KO-B5 and KO-B8 showed a more sustained tumor suppression effect than KO-dara. The infusion of CD38-CAR T cells in each group did not significantly affect the body weight of the mice.
[0245] Example 8. NK92 cells and culture methods
[0246] The complete culture medium for NK92 cells is AlphaMEM supplemented with 12.5% FBS, 12.5% Horse Serum, 1% Pen / Strep, 1% sodium pyruvate, 1% L-glutamine, and 100 U IL2. The complete culture medium for HL60, Molm13, KG-1, THP-1, and K562 cells is RPMI1640 supplemented with 10% FBS, 1% Pen / Strep, 1% sodium pyruvate, and 1% L-glutamine. Cells were cultured at 37°C, 5% CO2, and saturated humidity.
[0247] Example 9. CAR-NK92 lentiviral packaging and transfection
[0248] Resuscitation 293T inoculated one 150cm 2 The culture dish was placed in a CO2 incubator and cultured for 72 hours. After two passages, the culture dish was inoculated in a 150 cm 2 Culture dishes for transfection. Mix the four-plasmid system consisting of the lentiviral expression vector, helper plasmids gag / pol, Rev, and VSV-G with PEI transfection reagent, add to a defined volume of serum-free DMEM, mix thoroughly, and incubate for 15 minutes. Add this mixture to a 150 cm2 culture dish containing 293T cells, gently mix, and incubate in a 37°C, 5% CO2 incubator for 6 hours. After 6 hours, replace with fresh medium and continue incubation. Collect the lentiviral culture supernatant after 48 and 72 hours for infection. Transfer the harvested supernatant to a centrifuge tube and centrifuge at 4000 rpm for 10 minutes, with an ascending speed of 9 and a descending speed of 9, to remove cell debris. Filter and clarify the LVV supernatant through a 0.45 μm filter, and transfer the filtrate to a fresh centrifuge tube. Add the clarified lentiviral supernatant to an ultracentrifuge tube and balance on a scale. Place the balanced ultracentrifuge tubes into the hanging cups, which are then positioned in the corresponding positions of the rotor. Then, place the tubes in an ultracentrifuge and centrifuge at 4°C, 100,000 g, and 90 min, with both the ascent and descent speeds set to maximum. After ultracentrifugation, discard the supernatant, add 0.5 mL of culture medium to each tube, and resuspend at 2-8°C for 2 h. The harvested virus is then mixed with 1e6 NK92 cells in a 24-well plate and incubated in a CO2 incubator for 72 h.
[0249] Example 10. CAR-NK92 flow cytometry detection and sorting
[0250] Remove the cell suspension, wash three times with DPBS, centrifuge at 300g for 5 minutes, discard the supernatant, add the antibody cocktail (anti-FLAG-APC, 1:100 in DPBS), mix well, incubate at 4°C, stain for 30 minutes, wash three times with DPBS, and centrifuge at 300g for 5 minutes. Resuspend in DPBS and use for flow cytometry and flow sorting. During sorting, circle PE-positive cells and collect them in a 5ml flow cytometer. After sorting, centrifuge at 300g for 5 minutes, discard the supernatant, resuspend the cells in prewarmed culture medium, and incubate at 37°C, 5% CO2 in a cell culture incubator.
[0251] The sorted CAR-NK92 cells were stained with anti-FLAG-APC antibody, and the expression of CAR was detected by flow cytometry.
[0252] The results of flow cytometry are shown in FIG10 . The CAR positivity rate of the sorted CAR-NK92 cells reached over 97%.
[0253] Example 11. CAR-NK92 killing experiment
[0254] Luciferase-labeled tumor target cells were used to test their killing ability. By transferring the luciferase gene into target cells, stable cell lines expressing the luciferase gene were obtained for Molm13, HL60, THP-1, and KG1. During the experiment, luciferin substrate was added, and the luciferase reacted with luciferin to produce fluorescence. The intensity of the fluorescence was used to determine the activity of the luciferase, and the cell survival rate was measured to determine the killing effect of each CAR NK92 cell.
[0255] The results are shown in Figure 11. NK92 B8 showed more obvious killing on each target cell than NK92, suggesting a CAR-mediated killing effect.
[0256] Example 12. CAR-NK92 multiple rounds of killing experiments
[0257] One day before the experiment, THP1 cells with fluorescent target were resuspended and counted, and the cell density was adjusted to 8×10 4 / ml, 100ul per well of a 96-well plate. On the day of the experiment, take the corresponding number of NK92 and CAR-NK92 cells and add them to the wells. Place them in Cellcyte to start the experiment, and take pictures every 4 hours using bright field and fluorescence channels. Every two days is a round. After a round of killing, remove part of the supernatant, transfer it to a new plate with target cells, and place it in Cellcyte to start a new round of killing. The killing index is calculated by adjusting the zero-crossing time and the normal cell growth error, and then the reduction in the number of fluorescent cells is used to calculate the killing.
[0258] The results of multiple rounds of killing experiments are shown in Figure 12. NK92 B8 cells showed stronger killing ability than NK92 cells, suggesting that CAR-mediated killing is continuing to play a role.
[0259] Sequence information
[0260] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A nanobody that specifically binds to CD38, characterized in that: The complementary determining region CDR region of the VHH chain in the Nanobody has the following CDR1, CDR2 and CDR3: (a) CDR1: the sequence of which is shown in SEQ ID No: 6 or 11; (b) CDR2: the sequence of which is shown in SEQ ID No: 7, 9, 12 or 14; (c) CDR3: Its sequence is shown in SEQ ID No: 8, 10, 13 or 15.
2. The Nanobody according to claim 1, characterized in that The complementarity determining region CDR region of the VHH chain in the Nanobody is selected from the following group: (Y1) CDR1 of SEQ ID NO:6, CDR2 of SEQ ID NO:14, and CDR3 of SEQ ID NO:15; (Y2) CDR1 shown in SEQ ID NO:6, CDR2 shown in SEQ ID NO:9, and CDR3 shown in SEQ ID NO:10; (Y3) CDR1 shown in SEQ ID NO:6, CDR2 shown in SEQ ID NO:7, and CDR3 shown in SEQ ID NO:8; (Y4) CDR1 shown in SEQ ID NO:6, CDR2 shown in SEQ ID NO:9, and CDR3 shown in SEQ ID NO:10; (Y5) CDR1 shown in SEQ ID NO:11, CDR2 shown in SEQ ID NO:12, and CDR3 shown in SEQ ID NO:
13.
3. The Nanobody according to claim 1, characterized in that The amino acid sequence of the nanobody that specifically binds to CD38 is shown in any one of SEQ ID NOs: 1 to 5.
4. A multivalent antibody or an antibody against multiple epitopes that specifically binds to CD38, characterized in that: The multivalent antibody or antibody against multiple epitopes comprises at least one antibody element against the CD38 epitope, and the antibody element is the anti-CD38 nanobody according to claim 1.
5. A recombinant protein, characterized in that The recombinant protein has: (i) the CD38-specific binding nanobody of claim 1, or the CD38-specific binding multivalent antibody or antibody against multiple epitopes of claim 4; and (ii) optionally a tag sequence to facilitate expression and / or purification.
6. A chimeric antigen receptor (CAR) fusion protein, characterized in that The chimeric antigen receptor (CAR) fusion protein comprises from N-terminus to C-terminus: (i) an antigen binding domain that specifically binds to CD38, wherein the antigen binding domain comprises the Nanobody of claim 1; (ii) transmembrane domain; (iii) at least one co-stimulatory domain; and (iv) Activation domain.
7. The CAR fusion protein according to claim 6, characterized in that The CAR has a structure shown in Formula Ia: L-VHH-FH-TM-C-CD3ζ (Ia) In the formula, Each "-" is independently a connecting peptide or a peptide bond; L is the signal peptide sequence; VHH is an antigen binding domain that specifically binds to CD38; the amino acid sequence of the VHH is shown in any one of SEQ ID NOs: 1 to 5; F stands for Flag tag; H is the hinge region; TM is the transmembrane domain; C is the co-stimulatory signaling domain; CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ (including wild type, or mutant / modified form thereof).
8. The CAR fusion protein according to claim 6, characterized in that The CAR fusion protein has an amino acid sequence shown in any one of SEQ ID NOs: 25-29.
9. An antibody-drug conjugate, characterized in that: The antibody-drug conjugate contains: (a) the Nanobody according to claim 1, the multivalent antibody or the antibody against multiple epitopes according to claim 4, or the recombinant protein according to claim 5; as well as (b) a conjugated moiety conjugated to the antibody portion, wherein the conjugated moiety is selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, or a combination thereof.
10. A polynucleotide, characterized in that The polynucleotide encodes a protein selected from the group consisting of the nanobody of claim 1, the multivalent antibody or the antibody against multiple epitopes of claim 4, the recombinant protein of claim 5, or the CAR fusion protein of claim 6.
11. An expression vector, characterized in that: The expression vector contains the polynucleotide according to claim 10.
12. A host cell, characterized in that The host cell contains the expression vector of claim 11, or the polynucleotide of claim 10 is integrated into its genome, or expresses the nanobody of claim 1, the multivalent antibody or the antibody against multiple epitopes of claim 4, the recombinant protein of claim 5, or the CAR fusion protein of claim 6.
13. A pharmaceutical composition, characterized in that The pharmaceutical composition contains: (i) the Nanobody of claim 1, or the multivalent antibody or antibody against multiple epitopes of claim 4, or the recombinant protein of claim 5, or an immune cell expressing the CAR fusion protein of claim 6; and (ii) a pharmaceutically acceptable carrier.
14. Use of the nanobody according to claim 1, or the multivalent antibody or antibody against multiple epitopes according to claim 4, or the recombinant protein according to claim 5, or an immune cell expressing the CAR fusion protein according to claim 6, characterized in that: Used for preparing drugs for preventing and / or treating diseases related to CD38 positive expression.
15. A method for treating a disease, characterized in that: Comprising administering to a subject in need of treatment: The nanobody of claim 1, or the multivalent antibody or antibody against multiple epitopes of claim 4, or the recombinant protein of claim 5, or an immune cell expressing the CAR fusion protein of claim 6.
Citation Information
Patent Citations
CD38 nanometer antibody and application
CN103421115A
Single-domain antibody and its coding gene, immunotoxin and its coding gene, preparation method, expression vector and use and host cell
CN105837688A
Anti-CD38 nano-antibody, encoding gene and application
CN109232739A
Chimeric antigen receptor and application thereof
CN109232742A
Nano antibody capable of being combined with human CD38 and application thereof
CN111808193A
